Imatinib and Trametinib for KRAS-mutated Solid Tumor
Status:
RECRUITING
Trial end date:
2028-03-31
Target enrollment:
Participant gender:
Summary
In this pilot trial, participants with unresectable solid cancers harboring KRAS mutations will be provided with a compassionate treatment if their diseases progress after current standard treatments, or there is no available standard treatment. This trial will evaluate the efficacy and safety of the combination of trametinib and imatinib on chemotherapy refractory solid cancers.